Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Selected as a solid growth name with raised 2025 guidance supported by strong diagnostic product adoption and margin expansion; upcoming Nov 3 Q3 earnings represent key catalyst amid moderate technical weakness requiring caution.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Price Behavior
Key Price Behavior Insights: ⢠Support Holding ⢠Resistance Rejection ⢠Rebound Recovery Support Level: $540-$545 Resistance Level: $565-$576 Over the last month, IDXX rebounded from a late-June low and held the mid-$540s as support, but it remains capped below the $565-$576 resistance zone and needs to reclaim the upper-$550s to confirm a bullish continuation.
Sentiment & News
Key News Insights: ⢠Earnings Watch ⢠Valuation Compare ⢠Trading Signal IDXX is drawing steady attention ahead of earnings, with investors weighing growth appeal, valuation comparisons, trading signals, and modest institutional selling.
AI Summary
IDXX looks less like a âgood diagnostics companyâ and more like a premium growth compounder with accelerating recurring demand, but at a rich valuation the stock now depends on continued outsized execution and adoption of new products like inVue Dx and Cancer Dx to avoid multiple compression if Q2 is merely solid rather than exceptional.
Description
IDEXX Laboratories develops, manufactures, and sells diagnostic instruments, consumables, laboratory services, and practice management software for veterinary, livestock, dairy and water-testing markets worldwide. Its offerings include point-of-care and reference laboratory diagnostics, imaging and monitoring systems, and microbiological water tests, supported by sales, technical service teams and distribution partners. The company also supplies certain human point-of-care analyzers; it was founded in 1983 and is headquartered in Westbrook, Maine.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Nov 3 | Nov 10 | IDXX | IDEXX Laboratories, Inc. | Selected as a solid growth name with raised 2025 guidance supported by strong diagnostic product adoption and margin expansion; upcoming Nov 3 Q3 earnings represent key catalyst amid moderate technical weakness requiring caution. | Closed | -1.8% |